33). Chronically elevated inflammation and circulating insulin are two additional characteristics of T2D that have been proposed to promote tumor growth (33). It therefore makes sense that risk would be lowered by promoting better control of blood glucose levels in these individuals. The data in fact indicate that patients with T2D who receive GLP-1RAs and no longer require insulin had a lower incidence of cancers of the gastrointestinal tract compared with patients with T2D treated with supplemental insulin and no GLP-1 agonists (34). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.